Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03656536
Title A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

cholangiocarcinoma

Therapies

Pemigatinib

Cisplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST